Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001832 | 0.85 | CDK1 (0.45) | ALDH1A1MAPTSMN1; SMN2POLBKDM4E | |
| SCHEMBL4997964 | 0.81 | CNR2 (0.48) | SMN1; SMN2POLBGAAKMT2AMEN1 | |
| SCHEMBL3254162 | 0.79 | MAPT (0.41) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL4979922 | 0.75 | TUBB4A (0.46) | — | |
| SCHEMBL4348130 | 0.73 | EGFR (0.46) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL10323541 | 0.73 | MAPT (0.43) | ALDH1A1MAPTPOLBKDM4EGAA | |
| SCHEMBL13492133 | 0.73 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL3253017 | 0.73 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2GFERHSD17B10 | |
| SCHEMBL5754708 | 0.71 | MAPT (0.65) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL2854950 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-1833477-A1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | Novartis AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006063820-A1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | IL1R1, IL1A, IL1B | ALDH1A1 497/4885MAPT 3511/4885SMN1; SMN2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.